Drug intelligence / Profile preview

crizotinib + dasatinib

Development stage: Discontinued
Lead developer: University of Texas MD Anderson Cancer Center
Modality: Small Molecules
Administration: Oral

Overview

The combination of crizotinib and dasatinib is an investigational drug combination that has been studied in clinical trials for various cancer types. This combination targets multiple signaling pathways involved in cancer progression. It is a combination of crizotinib (a MET inhibitor) and dasatinib (a c-SRC inhibitor) investigated for the treatment of advanced cancers. Preclinical studies demonstrated cross-talk between MET and c-SRC molecules, suggesting potential synergistic effects. However, clinical trials showed limited tolerability due to high rates of adverse events and modest efficacy.

Targets

ALK (Anaplastic lymphoma kinase receptor tyrosine kinase)SFK (SRC family kinases)ROS1 (Proto-oncogene tyrosine-protein kinase ROS)MET (Mesenchymal-epithelial transition factor receptor)ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase)

Beyond the preview

Go deeper on crizotinib + dasatinib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on crizotinib + dasatinib.

Explore the full profile